Total Payments
$4,292
2024 Payments
$455.97
Companies
16
Transactions
197
Medicare Patients
641
Medicare Billing
$128,778
Payment Breakdown by Category
Food & Beverage$4,279 (99.7%)
Education$12.70 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,279 | 196 | 99.7% |
| Education | $12.70 | 1 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $2,571 | 106 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $563.70 | 39 | $0 (2024) |
| ABBVIE INC. | $408.26 | 14 | $0 (2024) |
| IRONWOOD PHARMACEUTICALS, INC | $127.41 | 6 | $0 (2020) |
| Braintree Laboratories, Inc. | $119.98 | 6 | $0 (2022) |
| RedHill Biopharma Inc. | $108.83 | 6 | $0 (2021) |
| Allergan Inc. | $104.40 | 6 | $0 (2018) |
| Celgene Corporation | $66.52 | 3 | $0 (2023) |
| Madrigal Pharmaceuticals | $51.59 | 2 | $0 (2024) |
| BOSTON SCIENTIFIC CORPORATION | $48.56 | 2 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $455.97 | 17 | Gilead Sciences, Inc. ($299.65) |
| 2023 | $381.82 | 13 | Gilead Sciences, Inc. ($282.15) |
| 2022 | $671.36 | 35 | Gilead Sciences, Inc. ($353.31) |
| 2021 | $1,020 | 46 | Gilead Sciences, Inc. ($364.60) |
| 2020 | $384.53 | 15 | Gilead Sciences, Inc. ($239.98) |
| 2019 | $586.99 | 23 | Gilead Sciences, Inc. ($460.94) |
| 2018 | $451.56 | 23 | Gilead Sciences, Inc. ($347.30) |
| 2017 | $339.30 | 25 | Gilead Sciences Inc ($222.89) |
All Payment Transactions
197 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/09/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $26.74 | General |
| Category: LIVER DISEASE | ||||||
| 11/27/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $16.64 | General |
| Category: Gastroenterology | ||||||
| 11/19/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $22.17 | General |
| 11/11/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $24.85 | General |
| Category: LIVER DISEASE | ||||||
| 11/04/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $32.75 | General |
| 10/16/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $33.30 | General |
| 10/14/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $18.87 | General |
| 10/05/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $29.17 | General |
| 08/28/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $20.99 | General |
| Category: Gastroenterology | ||||||
| 07/22/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $23.26 | General |
| Category: GASTROENTEROLOGY | ||||||
| 07/08/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $32.39 | General |
| 06/21/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $31.00 | General |
| 05/13/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $34.48 | General |
| 04/17/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $19.87 | General |
| Category: GASTROENTEROLOGY | ||||||
| 04/01/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $23.97 | General |
| Category: GASTROENTEROLOGY | ||||||
| 02/23/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $32.10 | General |
| 01/29/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $33.42 | General |
| 12/11/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $49.99 | General |
| 11/27/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $45.43 | General |
| 11/01/2023 | Intra-Sana Laboratories | RELTONE 200 MG (Drug), GLYCATE, RELTONE 400 MG | Food and Beverage | In-kind items and services | $12.87 | General |
| Category: GALLSTONES | ||||||
| 10/25/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $33.34 | General |
| 10/13/2023 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $24.62 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/20/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $32.52 | General |
| 07/26/2023 | ABBVIE INC. | VIBERZI (Drug), LINZESS | Food and Beverage | In-kind items and services | $19.58 | General |
| Category: GASTROENTEROLOGY | ||||||
| 05/17/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $34.96 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 169 | 182 | $162,200 | $36,355 |
| 2022 | 6 | 140 | 157 | $104,980 | $29,284 |
| 2021 | 8 | 203 | 230 | $191,780 | $48,356 |
| 2020 | 7 | 129 | 147 | $53,920 | $14,784 |
Total Patients
641
Total Services
716
Medicare Billing
$128,778
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Office | 2023 | 37 | 39 | $58,500 | $13,287 | 22.7% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Office | 2023 | 18 | 18 | $32,400 | $7,161 | 22.1% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Office | 2023 | 17 | 18 | $21,600 | $5,533 | 25.6% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Office | 2023 | 15 | 15 | $30,000 | $3,239 | 10.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 35 | 42 | $6,300 | $2,814 | 44.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 34 | 34 | $10,200 | $2,590 | 25.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 13 | 16 | $3,200 | $1,731 | 54.1% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Office | 2022 | 39 | 44 | $66,000 | $16,402 | 24.9% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Office | 2022 | 17 | 17 | $20,400 | $5,416 | 26.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 33 | 33 | $9,900 | $2,794 | 28.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 25 | 31 | $4,650 | $2,373 | 51.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 12 | 16 | $3,200 | $1,650 | 51.6% |
| 87811 | Detection test by immunoassay with direct visual observation for severe acute respiratory syndrome coronavirus 2 (covid-19) | Office | 2022 | 14 | 16 | $830.00 | $649.64 | 78.3% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Office | 2021 | 41 | 50 | $75,000 | $18,708 | 24.9% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Office | 2021 | 26 | 28 | $50,400 | $12,687 | 25.2% |
| 45380 | Biopsy of the large bowel using an endoscope (colonoscopy) | Office | 2021 | 20 | 20 | $40,000 | $5,391 | 13.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 38 | 42 | $8,400 | $4,584 | 54.6% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 27 | 27 | $8,100 | $2,754 | 34.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 13 | 13 | $4,550 | $2,056 | 45.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 18 | 21 | $3,300 | $1,633 | 49.5% |
| 99211 | Established patient outpatient visit, minimal presenting problem | Office | 2021 | 20 | 29 | $2,030 | $541.50 | 26.7% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Office | 2020 | 18 | 20 | $30,000 | $6,444 | 21.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 33 | 38 | $7,600 | $3,251 | 42.8% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 15 | 15 | $5,250 | $1,960 | 37.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 23 | 30 | $4,500 | $1,605 | 35.7% |
About Dr. Rene Eng, M.D
Dr. Rene Eng, M.D is a Gastroenterology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1629020151.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Rene Eng, M.D has received a total of $4,292 in payments from pharmaceutical and medical device companies, with $455.97 received in 2024. These payments were reported across 197 transactions from 16 companies. The most common payment nature is "Food and Beverage" ($4,279).
As a Medicare-enrolled provider, Eng has provided services to 641 Medicare beneficiaries, totaling 716 services with total Medicare billing of $128,778. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location New York, NY
- Active Since 05/16/2006
- Last Updated 06/20/2008
- Taxonomy Code 207RG0100X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1629020151
Products in Payments
- XIFAXAN (Drug) $560.87
- LINZESS (Drug) $238.28
- Epclusa (Drug) $125.00
- Talicia (Drug) $108.83
- Linzess (Drug) $108.32
- VIBERZI (Drug) $80.59
- ZEPOSIA (Drug) $79.22
- SUTAB (Drug) $74.13
- CREON (Drug) $73.72
- RESMETIROM (Drug) $51.59
- SUPREP BOWEL PREP (Drug) $30.62
- GENERAL BIOPSY (Device) $30.48
- DIFICID (Drug) $28.58
- IBSRELA (Drug) $24.62
- VOQUEZNA (Drug) $23.97
- PLENVU (Drug) $21.92
- RADIAL JAW (Device) $18.08
- SUPREP (Drug) $15.23
- RELTONE 200 MG (Drug) $12.87
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in New York
Arthur Kornbluth, Md, MD
Gastroenterology — Payments: $2.4M
Gastroenterology $2.4M
Dr. David Carr-Locke, Md Frcp Facg Masge, MD FRCP FACG MASGE
Gastroenterology — Payments: $2.3M
Gastroenterology $2.3M
Jean-Frederic Colombel, M.d, M.D
Gastroenterology — Payments: $1.1M
Gastroenterology $1.1M
Dr. Bruce Sands, Md, MD
Gastroenterology — Payments: $1.0M
Gastroenterology $1.0M
Ellen Scherl, Md, MD
Gastroenterology — Payments: $880,329
Gastroenterology $880,329
Sonal Kumar, Md, MD
Gastroenterology — Payments: $769,554
Gastroenterology $769,554